Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Expedia Group Inc (EXPE) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Expedia Group IncTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Expedia Group Inc vs Neurocrine Biosciences Inc — how do they compare? Expedia Group Inc trades at $322.17 (market cap $38.53B), while Neurocrine Biosciences Inc trades at $156.92 (market cap $16.46B). The key difference: Expedia Group Inc is far larger — about 2.3× Neurocrine Biosciences Inc's market cap, and Expedia Group Inc pays a 0.6% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

EXPENBIX
Market Cap
$38.53B$16.46B
Sector
Consumer CyclicalHealth
52-Week High
$321.07$185.50
52-Week Low
$188.51$123.10
Enterprise Value
$37.09B$16.48B
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Expedia Group Inc

Expedia Group (EXPE) trades at $321.5, up 2.39% today, with strong technical momentum and a bullish moving average crossover. The company reported robust Q2 2026 earnings, beating estimates with EPS of $5.76 versus $5.22 expected, driven by 14% revenue growth and record adjusted EBITDA of $1.1 billion (Business Wire, 2026-08-05). Fundamentals show high profitability with a 90.43% gross margin and improving net income, while valuation ratios like P/E of 20.19 and P/S of 2.59 reflect market confidence.

Outlook is positive with raised full-year revenue guidance to $16.05B-$16.22B (WSJ, 2026-08-05), supported by AI and B2B growth. Risks include competitive pressures and economic sensitivity. Analysts are mixed but lean bullish with a $322.95 consensus target, near the current price, suggesting limited upside but stability.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Expedia Group Inc

Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.

Read more on EXPE

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX